HIV Drugs Market Size- By Drug Class, By Administration, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecasts to 2032

Description

Global HIV Drugs Market Overview:

According to SPER Market Research, the Global HIV Drugs Market is estimated to reach USD 49.74 million by 2032 with a CAGR of 4.05%.

The chronic and potentially fatal human immunodeficiency virus (HIV) can be spread to humans to another through sexual contact and blood-to-blood contact. It is a virus that targets CD-4 cells, which are immunological cells, rendering the body more vulnerable to infections and other disorders. The demand for HIV medications has benefited from the increasing incidence of HIV illness throughout time. HIV medications assist in inhibiting HIV replication, hence lowering the risk of transmission. The increase in HIV prevalence and its diagnosis is one of the key reasons driving the growth of the worldwide market for HIV medications. In addition, a growth in the number of government activities aimed at raising public knowledge of causes, symptoms, and treatments has an impact on the market. The availability of generic medications, which are as effective and chemically equivalent to branded medications, is another factor influencing the demand for HIV medications.

Impact of COVID-19 on the Global HIV Drugs Market

Global healthcare goods import, and export have been hampered by the COVID-19 epidemic. Because of the disruption and volatility in the medicine supply, the pandemic has had a negative effect on the growth of this industry. Additionally, the demand for antiretroviral and antibiotic drugs has decreased internationally due to the decline in the number of new patient prescriptions in the United States, Europe, and other COVID-affected areas and nations. The majority of businesses have seen a negative effect of the epidemic on the sales of HIV/AIDS medications.

Scope of the Report:

Market size available for years: 2019-2032

Base year considered: 2021

Forecast period: 2022-2032

Segments covered: By Drug Class, By Administration, By Distribution Channel

Regions covered: North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Companies Covered: Abbvie Inc., Aelix Therapeutics, AIM ImmunoTech, BioNTech, Biosantech, Boehringer Ingelheim International GmbH, Bristrol-Myers Squibb Company, CytoDyn, Dewpoint Therapeutics, Gilead Sciences, GlaxoSmithKline, ImmunityBio, Janssen Pharmaceuticals, Japan Tobacco, Merck, Mylan, Roche, Shionogi, Starpharma, TaiMed Biologics, Theratechnologies, ViiV Healthcare.

Global HIV Drugs Market Segmentation:

By Drug Class: Based on the Drug Class, Global HIV Drugs Market is segmented as; Chemokine Receptor Inhibitors, Entry Inhibitors - CCR5 Co-Receptor Antagonist, Fusion Inhibitors, Integrate Inhibitors, HIV Integrase Strand Transfer Inhibitors, Multi-Class Combination Products, Protease Inhibitors, Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT's), Nucleoside Reverse Transcriptase Inhibitors (NRT's).

By Administration: Based on the Administration, Global HIV Drugs Market is segmented as; Oral, Parenteral.

By Distribution Channel: Based on the Distribution Channel, Global HIV Drugs Market is segmented as; Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Others.

By Region: The worldwide market may be divided into three regions based on geography: North America, Europe, and the rest of the world. It is expected that North America would predominate. The rising incidence of HIV infection among Americans is to blame for this region's dominance. The demand for HIV medications is greatly increased by a large patient base. The population's awareness is another element influencing the progress of the region. Additionally, the existence of major companies that provide cutting-edge HIV medications for the treatment of HIV infection will further accelerate market expansion. Rapid increase in the number of HIV infections and the abundance of HIV medicine manufacturers in this area, Europe is anticipated to be the second-largest market throughout the projection period.

Product Code: PHAR2213

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1 Research data source
- 2.1.1 Secondary data
- 2.1.2 Primary data
- 2.1.3 SPER's internal database
- 2.1.4 Premium insight from KOL's
2.2 Market size estimation
- 2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1 Drivers
- 4.1.2 Restraints
- 4.1.3 Opportunities
- 4.1.4 Challenges
4.2. COVID-19 Impacts of the Global HIV Drugs Market

5. Market variables and outlook

5.1. SWOT analysis
- 5.1.1 Strengths
- 5.1.2 Weaknesses
- 5.1.3 Opportunities
- 5.1.4 Threats
5.2. PESTEL analysis
- 5.2.1 Political landscape
- 5.2.2 Economic landscape
- 5.2.3 Social landscape
- 5.2.4 Technological landscape
- 5.2.5 Environmental landscape
- 5.2.6 Legal landscape
5.3. PORTER'S five forces analysis
- 5.3.1 Bargaining power of suppliers
- 5.3.2 Bargaining power of Buyers
- 5.3.3 Threat of Substitute
- 5.3.4 Threat of new entrant
- 5.3.5 Competitive rivalry
5.4. Heat map analysis

6. Global HIV Drugs Market, By Drug Class, 2019-2032 (USD Million)

6.1. Chemokine Receptor Inhibitors
6.2. Entry Inhibitors - CCR5 Co-Receptor Antagonist
6.3. Fusion Inhibitors
6.4. Integrate Inhibitors, HIV Integrase Strand Transfer Inhibitors
6.5. Multi-Class Combination Products, Protease Inhibitors
6.6. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT's)
6.7. Nucleoside Reverse Transcriptase Inhibitors (NRT's)

7. Global HIV Drugs Market, By Administration, 2019-2032 (USD Million)

7.1. Oral
7.2. Parenteral

8. Global HIV Drugs Market, By Distribution Channel, 2019-2032 (USD Million)

8.1. Hospital Pharmacies
8.2. Online Pharmacies
8.3. Others
8.4. Retail Pharmacies

9. Global HIV Drugs Market, By Region, 2019-2032 (USD Million)

9.1 North America
- 9.1.1 United States
- 9.1.2 Canada
- 9.1.3 Mexico
9.2 Europe
- 9.2.1 Germany
- 9.2.2 United Kingdom
- 9.2.3 France
- 9.2.4 Italy
- 9.2.5 Spain
- 9.2.6 Rest of Europe
9.3 Asia-Pacific
- 9.3.1 China
- 9.3.2 Japan
- 9.3.3 India
- 9.3.4 Australia
- 9.3.5 South Korea
- 9.3.6 Rest of Asia-Pacific
9.4 South America
- 9.4.1 Brazil
- 9.4.2 Argentina
- 9.4.3 Rest of South America
9.5 Middle East & Africa
- 9.5.1 Kingdom of Saudi Arabia
- 9.5.2 United Arab Emirates
- 9.5.3 Rest of Middle East & Africa

10. Company Profiles

10.1 Abbvie Inc.
- 10.1.1 Company details
- 10.1.2 Financial outlook
- 10.1.3 Product summary
- 10.1.4 Recent developments
10.2 Aelix Therapeutics
- 10.2.1 Company details
- 10.2.2 Financial outlook
- 10.2.3 Product summary
- 10.2.4 Recent developments
10.3 AIM ImmunoTech
- 10.3.1 Company details
- 10.3.2 Financial outlook
- 10.3.3 Product summary
- 10.3.4 Recent developments
10.4 BioNTech
- 10.4.1 Company details
- 10.4.2 Financial outlook
- 10.4.3 Product summary
- 10.4.4 Recent developments
10.5 Biosantech
- 10.5.1 Company details
- 10.5.2 Financial outlook
- 10.5.3 Product summary
- 10.5.4 Recent developments
10.6 Boehringer Ingelheim International GmbH
- 10.6.1 Company details
- 10.6.2 Financial outlook
- 10.6.3 Product summary
- 10.6.4 Recent developments
10.7 Bristrol-Myers Squibb Company
- 10.7.1 Company details
- 10.7.2 Financial outlook
- 10.7.3 Product summary
- 10.7.4 Recent developments
10.8 CytoDyn
- 10.8.1 Company details
- 10.8.2 Financial outlook
- 10.8.3 Product summary
- 10.8.4 Recent developments
10.9 Dewpoint Therapeutics
- 10.9.1 Company details
- 10.9.2 Financial outlook
- 10.9.3 Product summary
- 10.9.4 Recent developments
10.10 Gilead Sciences
- 10.10.1 Company details
- 10.10.2 Financial outlook
- 10.10.3 Product summary
- 10.10.4 Recent developments
10.11 GlaxoSmithKline
- 10.11.1 Company details
- 10.11.2 Financial outlook
- 10.11.3 Product summary
- 10.11.4 Recent developments
10.12 ImmunityBio
- 10.12.1 Company details
- 10.12.2 Financial outlook
- 10.12.3 Product summary
- 10.12.4 Recent developments
10.13 Janssen Pharmaceuticals
- 10.13.1 Company details
- 10.13.2 Financial outlook
- 10.13.3 Product summary
- 10.13.4 Recent developments
10.14 Japan Tobacco
- 10.14.1 Company details
- 10.14.2 Financial outlook
- 10.14.3 Product summary
- 10.14.4 Recent developments
10.15 Merck
- 10.15.1 Company details
- 10.15.2 Financial outlook
- 10.15.3 Product summary
- 10.15.4 Recent developments
10.16 Mylan
- 10.16.1 Company details
- 10.16.2 Financial outlook
- 10.16.3 Product summary
- 10.16.4 Recent developments
10.17 Roche
- 10.17.1 Company details
- 10.17.2 Financial outlook
- 10.17.3 Product summary
- 10.17.4 Recent developments
10.18 Shionogi
- 10.18.1 Company details
- 10.18.2 Financial outlook
- 10.18.3 Product summary
- 10.18.4 Recent developments
10.19 Starpharma
- 10.19.1 Company details
- 10.19.2 Financial outlook
- 10.19.3 Product summary
- 10.19.4 Recent developments
10.20 TaiMed Biologics
- 10.20.1 Company details
- 10.20.2 Financial outlook
- 10.20.3 Product summary
- 10.20.4 Recent developments
10.21 Theratechnologies
- 10.21.1 Company details
- 10.21.2 Financial outlook
- 10.21.3 Product summary
- 10.21.4 Recent developments
10.22 ViiV Heathcare
- 10.22.1 Company details
- 10.22.2 Financial outlook
- 10.22.3 Product summary
- 10.22.4 Recent developments